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INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2-C-Methyl
Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with
Excellent Pharmacokinetic and Pharmacodynamic Properties
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INX-08189 is an aryl-phosphoramidate of 6-O-methyl-2-C-methyl guanosine. INX-08189 was highly potent
in replicon assays, with a 50% effective concentration of 10 6 nM against hepatitis C genotype 1b at 72 h. The
inhibitory effect on viral replication was rapid, with a 50% effective concentration (EC50) of 35  8 nM at 24 h.
An intracellular 2-C-methyl guanosine triphosphate (2-C-MeGTP) concentration of 2.43  0.42 pmol/106
cells was sufficient to achieve 90% inhibition of viral replication. In vitro resistance studies confirmed that the
S282T mutation in the NS5b gene conferred an approximately 10-fold reduction in sensitivity to INX-08189.
However, the complete inhibition of S282T mutant replicons still could be achieved with an EC90 of 344  170
nM. Drug combination studies of INX-08189 and ribavirin indicated significant synergy in antiviral potency
both in wild-type and S282T-expressing replicons. Genotype 1b replicons could be cleared after 14 days of
culture when exposed to as little as 20 nM INX-08189. No evidence of mitochondrial toxicity was observed after
14 days of INX-08189 exposure in both HepG2 and CEM human cell lines. In vivo studies of rats and
cynomolgus monkeys demonstrated that 2-C-MeGTP concentrations in liver equivalent to the EC90 could be
attained after a single oral dose of INX-08189. Rat liver 2-C-MeGTP concentrations were proportional to dose,
sustained for greater than 24 h, and correlated with plasma concentrations of the nucleoside metabolite
2-C-methyl guanosine. The characteristics displayed by INX-08189 support its continued development as a
clinical candidate for the treatment of chronic HCV infection.
Hepatitis C virus (HCV) is one of the most important causes
of chronic liver disease worldwide (36). In the United States
alone, an estimated 3.9 million people are infected with HCV
(16), and an estimated 10,000 to 12,000 HCV-related deaths
occur annually (http://digestive.niddk.nih.gov/ddiseases/pubs
/chronichepc/).
The HCV inhibitory activity of 2-C-modified nucleosides
has been well studied and has been shown to specifically inhibit
HCV RNA replication both in biochemical assays and in cell-
based replicon assays (6). The corresponding intracellular
triphosphates of these 2-substituted nucleosides were potent,
competitive inhibitors of NS5B-catalyzed reactions in vitro.
The incorporation of the 2-modified monophosphates onto
the 3 end of the RNA strand resulted in the efficient termi-
nation of the elongation of the growing RNA chain. Accord-
ingly, 2-substituted nucleosides have been shown to function
as nonobligate chain terminators (5). Despite the potential of
2-C-modified nucleosides in the inhibition of RNA-dependent
RNA polymerase (RdRp) activity, they have failed to progress
as drug candidates due to one or more of the following: lack of
oral bioavailability, poor pharmacokinetic characteristics, lack
of cell penetration, and inefficient intracellular conversion to
the active triphosphate (6, 12, 28). For example, the triphos-
phate of 2-C-methyl guanosine (2-C-MeGTP) has been
shown to be a highly potent inhibitor of RdRp activity in
biochemical assays, and the nucleoside analog 2-C-methyl-
guanosine (2-C-MeG) had high oral bioavailability in rats,
but it lacked potency in cell-based subgenomic replicon as-
says (12, 28).
In an effort to unlock the potential of nucleoside NS5B
inhibitors, we have employed a phosphoramidate prodrug ap-
proach to improve upon the characteristics of cellular uptake
and intracellular activation. This approach is designed to by-
pass the rate-limiting initial phosphorylation step of activation
by delivering the monophosphate form of the nucleoside ana-
log to the liver, where it can be efficiently converted to the
active triphosphate (24). INX-08189 is a phosphoramidate of
O-6-methyl-2-C-methyl guanosine (Fig. 1) (26). This com-
pound was selected from a number of phosphoramidate can-
didates because of its significant potency in replicon assays and
its ability to efficiently generate intracellular triphosphate in
primary human hepatocytes (26).
The current study reports a detailed characterization of
INX-08189, including a description of its potency against mul-
* Corresponding author. Mailing address: Inhibitex, Inc., 9005
Westside Parkway, Alpharetta, GA 30009. Phone: (678) 746-1100. Fax:
(678) 746-1299. E-mail: jvernachio@inhibitex.com.
 Published ahead of print on 28 February 2011.
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tiple HCV genotypes, the relationship between potency and
intracellular 2-C-MeGTP production, the resistance geno-
types selected by the compound, and its pharmacokinetic and
pharmacodynamic properties in rats and primates.
MATERIALS AND METHODS
INX-08189. INX-08189 was synthesized in the laboratory of Christopher
McGuigan at the Welsh School of Pharmacy, Cardiff University, as described
previously (26).
Replicon assays. The HCV inhibitory activity of INX-08189 was evaluated in
replicon cell culture systems (Apath, LLC, Brooklyn, NY). For HCV genotype
1b (Con1), a Huh-7 cell line (29) expressing a stable, bicistronic subgenomic
replicon encoding the Renilla luciferase reporter gene was utilized (2). For HCV
genotype 2a (J6/JFH), Huh-7 cells were transfected transiently with a full-length,
monocistronic HCV genome construct expressing Renilla luciferase. The inhib-
itory effect on HCV RNA replication using the luciferase assay and the cytotoxic
effect of compounds were performed as previously described (24). For HCV
genotype 1a (H77), a stable, full-length, bicistronic replicon cell line was used (3).
Genotype 1a HCV RNA replication was monitored in this cell line using a
quantitative reverse transcriptase PCR assay (qRT-PCR; TaqMan) as follows.
Total RNA was isolated using the RNeasy 96 kit (Qiagen, Valencia, CA). The
RNA preparations were quantified using the RiboGreen RNA quantitation kit
(Invitrogen) and were used as the template in a qRT-PCR mixture containing 1
EZ buffer, 1Mn acetate, 300 M deoxynucleoside triphosphates (dNTPs), 1 l
(2.5 U) rTh, 300 nM primers specific for the HCV 3-untranslated region (UTR)
(forward, 5-GGCTCCATCTTAGCCCTAGTC-3; HCV-R, reverse, 5-AGTA
TCGGCACTCTCTGCAGT-3) and 150 nM TaqMan probe (6-carboxyfluores-
cein [FAM]-ATGCGGCTCACGGACC) (MGB probe). Amplification was per-
formed using an ABI 7500 real-time PCR system and the following thermal
cycling program: 95°C for 60 s and 60°C for 35 min, followed by 40 cycles of 95°C
for 45 s and 60°C for 45 s. The HCV RNA copy number was calculated from a
standard curve generated with synthetic HCV RNA standards of known concen-
trations.
Generation of NS5B mutant replicons. Mutations in the NS5B gene were
generated in the HCV genotype 1b (Con1) subgenomic replicon. To introduce
the S282T mutation in NS5B, a plasmid containing a restriction fragment incor-
porating the mutation (pT7GG-1b-S282T) was synthesized (Geneart Inc., Bur-
lingame, CA), and the restriction fragment was purified and used to replace the
corresponding fragment in the wild-type replicon. NS5B mutations I585T and
P540T were generated by in vitro mutagenesis using the QuikChange site-di-
rected mutagenesis kit (Stratagene, La Jolla, CA). Briefly, an XhoI/SpeI frag-
ment from the HCV genotype 1b replicon plasmid was cloned into pBluescript
SKII and used as the template for mutagenesis using the primers 5-TCTGTA
GGGGTAGGCACCTATCTACTCCCCAAC-3 and 5-GTTGGGGAGTAGA
TAGGTGCCTACCCCTACAGA-3 for I585T and 5-AACTCACTCCAATCA
CGGCTGCGTCCCAG-3 and 5-CTGGGACGCAGCCGTGATTGGAGTG
AGTT-3 for P540T. The XhoI/SpeI fragments containing the mutations then
were cloned into the HCV genotype 1b replicon plasmid. To generate the HCV
genotype 1b replicon carrying the NS5B double mutation S282TI585T, an SfiI
restriction fragment carrying the S282T mutation was used to replace the SfiI
fragment in the replicon containing the I585T mutation. The replicon carrying
NS5B mutations S96T and N142T was generated as follows. The S96T mutation
was generated by overlap extension PCR. In the first step, two overlapping PCR
fragments were amplified from the wild-type replicon using primers XhoI-F1
(5-GAA ATT CCC TCG AGC GAT GC-3), S96T-R1 (5-TTA GAT CTG
GCC GtA TGT GGG GGC GT-3), S96T-F2 (5-ACG CCC CCA CAT aCG
GCC AGA TCT AA-3), and MfeI-R2 (5-CAT GAT GGT GGT GTC AAT
TGG T-3) (underlining indicates the introduced restriction enzyme sites and
lowercase lettering indicates point mutations introduced by the oligonucleo-
tides). In the second step, the aforementioned overlapping PCR fragments were
used as the template in a PCR mixture containing primers XhoI-F1 (5-GAA
ATT CCC TCG AGC GAT GC-3) and MfeI-R2 (5-CAT GAT GGT GGT
GTC AAT TGG T-3). The N142T mutation was generated by PCR using
primers N142T-MfeI-F3 (5-ACC AAT TGA CAC CAC CAT CAT GGC AAA
AAcTGA GGT TTT CTG CG-3) and SfiI-R3 (5-TCG ACA GGC CGC AGC
GGC CTT-3). The two PCR fragments independently carrying S96T and N142T
were cloned into the genotype 1b replicon. All replicons containing altered NS5B
genes were confirmed by sequencing (SeqWright, Houston, TX).
Transient transfection of NS5B mutant replicons. Replicon RNA for trans-
fection was prepared as follows. Replicon plasmid DNA was linearized with ScaI
(Fermentas, Glen Burnie, MD) and used for in vitro reverse transcription using
the T7 MegaScript kit (Ambion, Austin, TX). The DNA template was removed
by digestion with Turbo DNase, and the RNA was precipitated with 2.5 M LiCl.
RNA was quantified using the Quant-iT RiboGreen RNA kit (Molecular Probes,
Eugene, OR). In preparation for transfection, Huh-7 cells were cured of repli-
cons by prolonged treatment with alpha interferon 2A (IFN--2A). Cured Huh-7
cells were treated with trypsin, washed three times with ice-cold phosphate-
buffered saline (PBS; Invitrogen, Carlsbad, CA), and resuspended at 1.6 107
cells/ml in PBS. Ten g of replicon RNA was combined with 0.35 ml of cell
suspension and immediately pulsed three times (800 V, 100 s) using a BTX
ElectroSquare Porator ECM 830 (Harvard Apparatus, Holliston, MA). Electro-
porated cells were incubated at room temperature for 10 min prior to resuspen-
sion in 20 ml of Dulbecco’s modified essential medium (DMEM)-high glucose
medium (HyClone, Logan, UT) supplemented with 9% fetal bovine serum (FBS)
(HyClone), 2 mM glutamine (Invitrogen), and 100 U/ml PenStrep (Invitrogen).
Resuspended cells were plated into 96-well BioCoat collagen-treated tissue cul-
ture plates (VWR, West Chester, PA).
HCV replicon clearance studies. HCV replicon 1b cells were seeded in 6-well
plates at 1  105 cells/well without the selective antibiotic G418. INX-08189 was
added to cell cultures 4 h after seeding at the following final concentrations: 0
nM (control), 5, 10, 20, 40, and 80 nM. The medium was changed daily, and the
cells were subcultured on days 5 and 10. On days 0, 5, 8, 10, 12, and 14, the cell
cultures were analyzed for HCV genome-encoded Renilla luciferase expression
with the Renilla luciferase assay kit (Promega, Madison, WI) using a Veritas
luminometer (Turner Biosystems, Sunnyvale, CA). On days 5, 10, and 14, a
portion of the INX-08189-treated and control cell cultures were seeded into T-75
tissue culture flasks and incubated without INX-08189 but in the presence of 0.5
mg/ml of the selective antibiotic G418 (Invitrogen, Carlsbad, CA). As these
secondary cultures grew, individual flasks were fixed and stained with crystal
violet. For cultures where there were no visible surviving colonies, the flasks were
stained after 5 weeks of G418 selection.
Measurement of intracellular 2-C-methyl-GTP in vitro. Genotype 1b replicon
cells were seeded into six-well plates at 6  105 cells/well for 18 h before being
cultured in the presence of INX-08189 for 6 h. Cell samples were harvested and
extracted with 70% ethanol overnight at 4°C, and extracts were dried overnight
under a stream of nitrogen. The dried extracts were reconstituted with 50 l of
10 mM N,N-dimethylhexylamine, 3 mM ammonium formate in H2O. A standard
curve was generated by spiking blank cell extract samples with known concen-
trations of 2-C-MeGTP. Spiked samples were treated identically to the test
samples, and processed samples were kept at 2 to 8°C before and during analysis.
Endogenous ATP and GTP levels were monitored as internal quality controls of
cell viability and extraction efficiency. Liquid chromatography coupled to tandem
mass spectrometry (LC-MS/MS) analysis was performed with an Agilent 1100
series high-performance liquid chromatograph (HPLC) equipped with an
XTerra MS C18, 3.5 M, 2.1- by 50-mm column (Waters, Milford, MA) and an
API 4000 mass spectrometer (Aplied Biosystems, Carlsbad, CA) using negative-
ion polarity. The assay was linear (r2  0.99) in the concentration range of 1 to
1,000 ng per 106 cells, with 90% accuracy and 10% coefficient of variation
(CV).
Drug combination studies in genotype 1b replicon assay. Compounds were
tested both as single agents and in the following combinations: INX-08189 with
IFN--2B (ProspecBio, Rehovot, Israel) and INX-08189 with ribavirin (Rbv;
Research Products, Mt. Prospect, IL). Inhibition data from the replicon cultures
was analyzed for drug interactions using a three-dimensional surface model
based on the Bliss independence effects definition for additivity (MacSynergy II;
obtained from M. N. Prichard, K. R. Aseltine, and C. Shipman, University of
Michigan) (32). As suggested by the software authors and as utilized by others,
volumes of synergy or antagonism greater than 25 M2% were considered minor
FIG. 1. Structure of INX-08189: (2S)-neopentyl 2-(2R,3R,4R)-5-
(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahy-
drofuran-2-yl)(methoxy)(naphthalen-1-yloxy)(phosphorylamino)
propanoate.
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but significant, volumes greater than 50 M2% were considered moderate and
potentially important in vivo, and values greater than 100 M2% indicate strong
synergy and probable importance in vivo (10).
Pharmacokinetic studies of rats. Rat studies were conducted at Inhibitex, Inc.,
in accordance with NIH guidelines and by following protocols approved by the
Institutional Animal Care and Use Committee (IACUC) of Inhibitex, Inc. INX-
08189 was formulated in 95% Capmul MCM (Abitec Corp., Janesville, WI)–5%
Tween 80 (Sigma, St. Louis, MO) and administered by oral gavage to male
Sprague-Dawley rats (Taconic Farms, Germantown, NY). Blood and tissue col-
lections were performed as a terminal procedure. Oral doses ranged from 3 to 25
mg/kg of body weight, and sampling times were 1, 2, 4, 8, 16, 24, 72, 96, and 168 h
postadministration. Time points were selected to measure 2-C-MeGTP concen-
trations at both the time to maximum concentration of drug in serum (Tmax) and
at the trough (24 h). To study the relationship between liver 2-C-MeGTP levels
and plasma 2-C-MeG concentrations, the oral dose range was expanded to 3 to
300 mg/kg, approximating human equivalent doses of 30 to 3,000 mg. Plasma
samples were collected at 1, 2, 4, 8, 16, 24, 72, 96, and 168 h postadministration
and correlated to trough levels of 2-C-MeGTP in liver samples collected 24 h
postadministration. Blood was collected into EDTA-containing tubes (1.6 mg
EDTA/ml blood; Sarstedt, Inc., Newton, NC), and the plasma was separated by
centrifugation within 30 min of collection. Liver samples were snap frozen im-
mediately upon collection in liquid nitrogen. Plasma and liver samples were
stored frozen at 80°C prior to analysis.
Pharmacokinetic studies of cynomolgus monkeys. Primate studies were con-
ducted at MPI Research Inc., of Mattawan, MI, in accordance with protocols
approved by the IACUC of MPI Research Inc. INX-08189 was formulated in 5%
(vol/vol) dimethylacetamide–20% (vol/vol) Solutol HS 15–20% (vol/vol) poly-
ethylene glycol 400–55% (vol/vol) 50 mM sodium acetate, pH 4.0, and was
administered as a single oral gavage dose. The dose level of 25 mg/kg was chosen
for comparison to the equivalent dose of 50 mg/kg in rats. Liver biopsy samples
(four to five samples/animal) were collected from two animals/group/time point
at 3 and 8 h postdose in an effort to measure 2-C-MeGTP levels near the Tmax.
Anesthesia was induced and maintained, and pre- and postoperative procedures
were performed according to MPI Research standard operating procedures. The
liver biopsy samples were pooled for each animal. Blood samples (approximately
1.2 to 2.0 ml) were collected into tubes containing sodium heparin from the
femoral artery/vein or from the portal vein cannula at 0.5, 1, 2, 3, 4, 8, 12, and
24 h postadministration. Time points were selected to measure 2-C-MeG con-
centrations at both the Tmax and at the trough (24 h). Plasma was separated by
centrifugation and stored frozen until analysis.
Bioanalysis of pharmacokinetic samples. The concentration of 2-C-MeGTP
in liver samples and the concentration of 2-C-MeG in plasma samples from rats
and primates was performed by LC-MS/MS as described previously (24). The
assay measuring 2-C-MeGTP in rat or primate liver was linear (r2  0.99) in the
concentration range of 100 to 4, 000 ng per g of tissue, with 85% accuracy and
2% CV. The assay measuring 2-C-MeG in rat or primate plasma was linear (r2
 0.99) in the concentration range of 2 to 1,250 ng/ml, with 90% accuracy and
2% CV. The concentrations of INX-08189 in plasma samples collected from
primates were measured by LC-MS/MS as follows. Fifty l of each test sample
was added to 200 l of acetonitrile containing an internal standard. The samples
were centrifuged at 1,300  g at 4°C for 20 min, and 50 l of supernatant from
each sample was diluted with 50 l H2O. Samples were covered, mixed by being
vortexed, and maintained at 2 to 8°C before and during analysis. Calibration
curves were generated by spiking various concentrations of INX-08189 into
control plasma samples. Fifteen l of each test sample was analyzed by LC-MS/
MS. Liquid chromatography was performed with an Agilent 1100 series HPLC
system equipped with a Synergi 4-m Polar-RP 30- by 2.0-mm column (Phe-
nomenex, Torrance, CA). The HPLC system was coupled to an API 4000 triple-
quadrupole mass spectrometer (Applied Biosystems, Framingham, MA). Mass
spectrometry was performed in positive-ion mode, and data were analyzed using
Analyst v1.4.2 software (Applied Biosystems, Framingham, MA). The assay was
linear (r2  0.99) in the concentration range of 10 to 1,000 ng/ml, with 90%
accuracy and 10% CV.
Pharmacokinetic analysis. Noncompartmental pharmacokinetic analyses were
performed on the plasma and liver concentration data for the analytes using
WinNonlin v5.2 software (Pharsight, St. Louis, MO). The extravascular dosing
pharmacokinetic model was used to calculate the pharmacokinetic parameters,
which included maximum observed concentration (Cmax), time at maximal con-
centration (Tmax), terminal half-life (t1/2), and trapezoidal area determined from
the plasma concentration time data from time zero to last observed concentra-
tion (AUC0-t), from time 0 to 24 h (AUC0-24), and from time 0 extrapolated to
infinity (AUC0-). Estimates for the terminal half lives were obtained using
regression analysis. Values that were below the lower limit of quantitation were
assigned the value of zero for the analyses.
Mitochondrial toxicity assay. Mitochondrial toxicity was measured by analyz-
ing the ratio of the mitochondrial genome copy number to a nuclear gene copy
number before and after drug treatment. The mitochondrial target sequence
corresponded to the region between the genes TRNL1, encoding tRNA-leu, and
ND1, encoding NADH dehydrogenase subunit 1, and the cellular genome com-
parator was the ß-globin gene (7). Total DNA from untreated CEM cells was
serially diluted and used to generate a standard curve for determining the
absolute copy number of the gene targets. After drug treatment, total DNA was
isolated from treated cells using the DNeasy tissue kit (Qiagen, Valencia, CA).
The purified DNA was quantified by spectrophotometry using a Spectramax M2
plate reader (Molecular Devices, Sunnyvale, CA). Duplex quantitative PCR was
performed in an ABI 7500 real-time PCR system (Applied Biosystems, Foster
City, CA) using a 25-l reaction volume containing 1 QuantiTect multiplex
PCR (with 6-carboxy-X-rhodamine) mix; 250 nM mitochondrion-specific primers
5-CCACCCAAGAACAGGGTTTG-3 (forward) and 5-TAAGAAGAGGAA
TTGAACCTCTGACTG-3 (reverse); 250 nM mitochondrion-specific probe
FAM-5-TAAGATGGCAGAGCCCGGTA-3-minor groove binding nonfluo-
rescent quencher (MGBNFQ); 500 nM -globin-specific primers 5-GTGGAT
GAAGTTGGTGGTGAGG-3 (forward) and 5-CTCCACATGCCCAGTTTC
TATTG-3 (reverse); 250 nM globin-specific probe VIC-5-CCTGGGCAGGT
TGGTA-3-MGBNFQ (Integrated DNA Technologies, Coralville, IA); and
genomic DNA template. Amplification was carried out using the following ther-
mal cycling program: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and
then 60°C for 1 min. The ratios between mitochondrial and cellular genome copy
numbers were derived for each sample and compared to those of control cul-
tures. Changes in mitochondrial copy number were expressed as a percent
difference from the control value.
RESULTS
Activity of INX-08189 against wild-type HCV replicons. The
HCV inhibitory activity of INX-08189 was evaluated in repli-
cons expressing HCV genomes from genotypes 1a, 1b, and 2a.
INX-08189 was found to be a highly potent inhibitor of HCV
replication, with EC50s of 10 nM against genotype 1b, 12 nM
against genotype 1a, and 0.9 nM against genotype 2a after 72 h
of exposure (Table 1). Following 72 h of exposure, the con-
centration resulting in 50% cellular cytotoxicity (CC50) in cul-
tured Huh-7 cells was 7.01 M, resulting in therapeutic indices
ranging from 584 to 7,778.
To determine the magnitude of HCV inhibitory activity that
could be achieved with less than 72 h of incubation, genotype
1b replicon cells were incubated with INX-08189 for 24 or 48 h,
and the EC50s and EC90s were determined (Table 1). Similar
levels of potency were observed when cells were incubated with
INX-08189 for 48 or 72 h. If exposure time was reduced to only
24 h, the concentration required to achieve the EC50 level
increased 3.5-fold; however, INX-08189 still was able to inhibit
HCV replication by 90% (EC90 	 0.6 M).
Intracellular metabolism in HCV replicon cells. The intra-
cellular conversion of INX-08189 to 2-C-MeGTP was deter-
TABLE 1. INX-08189 potency in wild-type repliconsa
HCV
genotype
Incubation
period (h) EC50 (M) EC90 (M)
CC50 (M)
for Huh-7
1b 24 0.035 
 0.008 0.600 
 0.453
1b 48 0.011 
 0.005 0.061 
 0.033
1b 72 0.010 
 0.006 0.038 
 0.020 7.01 
 1.97
1a 72 0.012 
 0.004 0.042 
 0.011 7.01 
 1.97
2a 72 0.0009 
 0.0001 0.0065 
 0.001 7.01 
 1.97
a All data are means 
 standard deviations from at least three independent
experiments.
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mined in genotype 1b replicon cells. Replicon cells were incu-
bated with concentrations of INX-08189 that produce 50%
inhibition of HCV replication (EC50 	 10 nM), 90% inhibition
(EC90 	 40 nM), and twice the EC90 (2 EC90 	 80 nM).
Cells were harvested after 6 h of exposure to INX-08189, and
the intracellular 2-C-MeGTP concentrations were measured
(Table 2). There was a linear relationship (R2 	 0.91) between
the measured intracellular 2-C-MeGTP concentrations and
the concentrations of INX-08189. At 40 nM INX-08189, the
concentration of 2-C-MeGTP in Huh-7 cells was 2.43 
 0.42
pmol/1  106 cells. Given an estimated liver cellularity of 1 
108 cells per g (37), the intracellular concentration of 2-C-
MeGTP that would be expected to result in 90% viral inhibi-
tion in liver tissue was calculated to be 243 pmol/g of tissue.
This value was useful for interpreting the relevance of liver
2-C-MeGTP levels measured in subsequent in vivo pharma-
cokinetic studies.
To determine the intracellular half-life of 2-C-MeGTP, ac-
tively dividing genotype 1b replicon cells were incubated with
1 M INX-08189 for 8 h, at which time the drug was removed.
Intracellular 2-C-MeGTP levels were measured at 12, 24, 32,
48, and 56 h after the drug was initially added (Fig. 2). Based
on these data, the half-life of intracellular 2-C-MeGTP in
Huh-7 cells was calculated to be approximately 24 h.
Selection and characterization of mutants resistant to INX-
08189. To determine the resistance mutations selected by INX-
08189, long-term cultures of genotype 1b and 1a replicons were
performed in the presence of G418 and with concentrations of
INX-08189 that were increased up to eight times the EC50 (80
nM) in the 1b replicon and 4 the EC50 (40 nM) in the 1a
replicon. The establishment of stable INX-08189 escape mu-
tants was significantly delayed, requiring selection during a 6-
to 9-week span in culture. In total, five single-colony-derived
resistant cell lines were selected in the genotype 1b back-
ground, and one was selected in the genotype 1a background.
The nucleotide sequences of the NS5B genes from these clones
were determined. Two consistent NS5B mutations, a codon
282 alteration from serine to threonine (S282T) and a change
in amino acid position 585 from isoleucine to threonine
(I585T), were identified in drug-resistant clones from the ge-
notype 1b background. The S282T substitution had been iden-
tified previously as a resistance mutant for 2-C-Me-GTP (28).
In the single clone derived from the genotype 1a replicon
selection, the only alteration in the NS5B gene sequence was a
codon change from alanine to threonine in amino acid position
540 (A540T in genotype 1a). To determine if these amino acid
substitutions were sufficient to confer resistance to INX-08189,
they were introduced singly or in combination into the geno-
type 1b replicon background, and potency was assessed in a
transient replication assay. For comparative purposes, a repli-
con carrying the substitutions S96T and N142T that has been
shown to confer resistance to 4-azidocytidine (R1479) (20)
was tested in parallel. INX-08189 potency against each of these
mutant replicons and their relative replication competencies
are summarized in Table 3. The presence of the S282T muta-
tion resulted in drastically reduced replication efficiency, at
approximately 4% of the rate of the wild-type replicon. Com-
bining the I585T mutation with S282T improved replication
efficiency to 8% of the wild-type level. INX-08189 potency
against S282T mutant replicons was reduced approximately
10-fold, while INX-08189 potency against all other mutant
replicons tested was unaffected, suggesting that S282T was
sufficient to produce an INX-08189-resistant phenotype. De-
spite the shift in potency observed, exposure to INX-08189 still
could significantly inhibit HCV replication in the S282T mu-
tant replicons with an EC90 of 344 
 170 nM (Fig. 3).
Effect of combining INX-08189 and Rbv. In clinical trials,
INX-08189 likely will be used in combination with standard
therapy, which currently consists of pegylated interferon and
Rbv. We therefore characterized the INX-08189 resistance
mutant S282T as well as the other mutant replicons for their
sensitivity to both Rbv and alpha interferon 2b (Table 3).
Replicons expressing S282T proved to be more sensitive to the
inhibitory activity of ribavirin, with an approximately 6-fold
improvement in the EC50, whereas the potency of IFN- was
equivalent across all mutants tested. The difference in ribavirin
potency between wild-type and S282T mutants was significant
(P 	 0.0093, unpaired t test with Welch’s correction.) To ex-
plore this effect further, drug combination studies of INX-
08189 paired with Rbv were carried out in both wild-type and
transiently expressed S282T replicons (Table 3). The combi-
nation of INX-08189 and Rbv was highly synergistic in the
wild-type replicon, with a synergy volume of 808 M2%. Like-
wise, INX-08189 combined with Rbv against replicons express-
ing the S282T mutation was found to be significantly synergis-
tic (117 M2%).
Clearance of replicons. To assess the antiviral effect of long-
term treatment with INX-08189 on HCV replication, genotype
FIG. 2. Determination of 2-C-MeGTP intracellular half-life in ge-
notype 1b replicon. Genotype 1b replicon cells were incubated with 1
M INX-08189 for 8 h, at which point the drug was removed. Intra-
cellular 2-C-MeGTP concentrations were measured by LC-MS/MS.
Symbols are means 
 SD for triplicate determinations in a single
experiment.
TABLE 2. Intracellular 2-C-methyl GTP in genotype 1b replicon
upon incubation with INX-08189a
INX-08189
concn (nM)
Amt of intracellular
2-C-methyl GTP
(pmol/106 cells)
Estimated equivalent
liver concnb
(pmol/g tissue)
1 EC50 (10) 0.84 
 0.36 84
1 EC90 (40) 2.43 
 0.42 243
2 EC90 (80) 4.97 
 0.80 497
a All values are means 
 standard deviation from six determinations, all mea-
sured at 6 h of incubation with INX-08189.
b Estimates are based on a liver cellularity of 1  108 cells per g.
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1b replicon cells were cultured in the presence of 0 (control),
5, 10, 20, 40, or 80 nM INX-08189 for 14 days in the absence
of G418 selection. At various time points during the culture
period, cell samples were harvested and luciferase expression
was determined as a measure of HCV replication activity. As
summarized in Fig. 4A, luciferase activity in treated cultures
decreased over time compared to that of the control, and
inhibition was concentration dependent. Culturing in the pres-
ence of 10 nM INX-08189 resulted in a 2 log10 reduction in
HCV replication activity. Culturing in the presence of20 nM
(2 EC50) resulted in a 5 log10 reduction in HCV replica-
tion activity after 12 days. After 14 days of culture at concen-
trations of 40 nM (1 EC90), HCV replication activity was
reduced to background levels. Samples of the treated cells
were harvested at days 5, 10, and 14 and subcultured without
INX-08189 but in the presence of G418. Any cells remaining in
the cultures that retained the expression of the replicon ge-
nome would be resistant to G418 selection and after sufficient
time in culture would be detected as visibly growing colonies
(Fig. 4B). Cultures that were incubated in the presence of
INX-08189 for only 5 days retained the expression of the rep-
licon at all concentrations tested, although the frequency of
expressing colonies diminished with increasing INX-08189
concentration. After 10 days of INX-08189 treatment, repli-
con-expressing cells were completely eliminated at concentra-
tions of 40 nM (1 EC90). After 14 days of INX-08189
treatment, replicon-expressing cells were completely elimi-
nated from the culture at concentrations of 20 nM (2
EC50).
Mitochondrial toxicity. Mitochondrial toxicity has been de-
scribed as a manifestation of an adverse effect associated with
the long-term use of certain nucleoside analogs (15). To eval-
FIG. 3. Inhibition of HCV replication. Representative inhibition
curves are plotted for replicons expressing wild-type (●), S282T (),
I585T (f), A540T (), S282T/I585T (), and S96T/N142T (}) NS5B
sequences. Concentrations of INX-08189 are indicated on the x axis,
and the measured luminescent signals are expressed as a percentage of
signal obtained in no-treatment controls on the y axis. Symbols are
means 
 SD for triplicate determinations in a single experiment.
TABLE 3. INX-08189 potency against transient replicons expressing mutant NS5Ba
NS5B sequence Replicationefficiencyc (%)
EC50 of: INX-08189  Rbv
synergyd (M2%)INX-08189 (M) Rbv (M) IFN- EC50 (IU)
Con1 WT 100 0.006 
 0.003 12.157 
 1.753 4.974 
 1.511 808
S282T 4 0.074 
 0.026 1.728 
 0.016 3.116 
 0.439 117
I585T 165 0.005 
 0.001 15.247 
 1.639 3.380 
 1.383
A540Tb 86 0.004 
 0.001 17.250 
 3.235 3.294 
 1.251
S282T/I585T 8 0.055 
 0.018 1.736 
 0.110 1.937 
 0.662
S96T/N142T 102 0.006 
 0.001
a All data are averages 
 standard deviations from at least three independent experiments.
b The genotype 1b strain Con1 encodes a proline at position 540, as opposed to the alanine in genotype 1a strain H77.
c Percent luciferase activity compared to activity of the wild-type replicon.
d Bliss independence effects definition for additivity (MacSynergy II).
FIG. 4. Clearance of wild-type replicons in vitro with INX-08189.
(A) Huh-7 genotype 1b replicons cells were cultured in the presence of
INX-08189 without G418 for 14 days at concentrations of 5 (●), 10 (),
20 (f), 40 (E), and 80 nM (}). Luciferase expression was monitored in
the cultures at the indicated time points and expressed as log10 change in
luminescence. (B) Cells were subcultured under G418 selection for up to
5 weeks, and surviving colonies were fixed and stained with crystal violet.
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uate the effect of INX-08189 on the relative mitochondrial
genome copy number in the human cell lines CEM and
HepG2, both a 3- and 14-day study were conducted. Mitochon-
drial copy numbers were determined after treatment with
INX-08189 in CEM, a lymphocyte cell line, and HepG2, a
human hepatocyte cell line. To distinguish mitochondrion-spe-
cific toxicity from general cellular cytotoxicity, increasing con-
centrations of INX-08189 were evaluated in the cell lines for 3
and 14 days. INX-08189 concentrations that did not affect
overall cell viability were selected for the mitochondrial toxic-
ity assessment. The maximum INX-08189 concentrations eval-
uated for mitochondrion-specific toxicity were 20 and 5 M in
CEM and HepG2 cells, respectively, treated for 3 days. In the
14-day experiments, the maximum INX-08189 concentration
was 1 M in both CEM and HepG2 cells. In CEM cells treated
with a 20 M concentration of INX-08189 for 3 days, the
reduction in relative mitochondrial copy number was approx-
imately 11% (Table 4). There were no effects on mitochondrial
copy number observed in CEM cells at 1 M for 14 days. The
relative mitochondrial copy number in HepG2 cells was calcu-
lated to be 129 and 115% at 5 and 1 M drug in 3- and 14-day
treatments, respectively, demonstrating that INX-08189 did
not alter the relative mitochondrial copy number in HepG2
cells. In contrast, a positive-control compound, dideoxycyto-
sine (ddC), reduced the relative mitochondrial numbers by 56
and 69% in the 3-day study in CEM and HepG2 cells, respec-
tively. Culturing CEM and HepG2 cells for 14 days with ddC
resulted in mitochondrial copy number reductions of 80 and
99%, respectively (Table 4).
Pharmacokinetics in rats. The ability of INX-08189 to de-
liver a monophosphate form to the liver that subsequently is
converted to 2-C-Me-GTP after oral administration was
tested in Sprague-Dawley rats. 2-C-MeGTP concentrations
were measured in rat liver samples harvested during a 7-day
period (Fig. 5). At doses of 5 mg/kg, the concentrations of
2-C-MeGTP in the liver exceeded the EC90 soon after dosing
and remained at or above this level for 72 h.
The measurement of 2-C-MeGTP in liver tissue is the most
direct approach for determining the bioavailability of INX-
08189; however, the use of this analytical tool is limited in
higher species, as it can be employed only at a few time points
and is impractical for pharmacokinetic studies of humans. An-
other approach is to monitor the generation of a metabolite of
INX-08189 in the plasma that is proportional to the production
of 2-C-MeGTP in the liver. To this end, the plasma levels of
2-C-MeG, a major metabolite of INX-08189, were measured
in the rat. The plasma AUC0-24 (in ng  h/ml) values of 2-C-
MeG were compared to the 2-C-MeGTP C24 (ng/g) concen-
trations after the administration of oral doses ranging from 3
to 300 mg/kg (Table 5). At doses between 3 and 150 mg/kg,
both the 2-C-MeG plasma AUCs (ng  h/ml) and the 2-C-
MeGTP liver concentrations (ng/g) at 24 h were found to be
dose proportional and linear, with R2 values equal to 0.96 and
0.99, respectively. In addition, the 2-C-MeG plasma AUCs
and the 2-C-MeGTP liver C24 also were found to be highly
correlative (R2 	 0.97) at doses between 3 and 150 mg/kg. This
correlation was not maintained at the 300-mg/kg dose. These
data validate the utility of measuring 2-C-MeG exposure in
the plasma as a biomarker to monitor the liver pharmacoki-
netics of 2-C-MeGTP in vivo.
TABLE 4. Mitochondrial toxicity
Cell line Compound
Relative mitochondrial copy
no.a (% of control) on
treatment day:
3 14
CEMb INX-08189 89 
 11 102 
 14
2-C-MeG 109 
 43 133 
 4
ddC 31 
 5 1 
 1
HepG2c INX-08189 129 
 22 115 
 23
2-C-MeG 103 
 57 137 
 2
ddC 44 
 16 20 
 24
a Measured as the ratio between mitochondrial genome copy number and
cellular genome copy number compared to values for untreated control cultures.
Values are averages from at least two experiments 
 standard deviations.
b Concentrations used for 3-day cultures were 20M INX08189, 100 M
2-C-MeG, and 5M ddC, and those for 14-day cultures were 1 M INX08189,
100 M 2-C-MeG, and 0.5 M ddC.
c Concentrations used for 3-day cultures were 5M INX08189, 100 M 2-C-
MeG, and 10M ddC, and those for 14-day cultures were 1 M INX08189, 100
M 2-C-MeG, and 2M ddC.
FIG. 5. Concentrations of 2-C-methyl GTP in rat liver following
oral dosing with INX-08189. Each line represents a separate dose
level: 25 mg/kg (}), 10 mg/kg (), 5 mg/kg (f), and 3 mg/kg (E).
Symbols represent averages from two rats with the exception of the
3-mg/kg dose group, which included data from six rats. The EC90
determined for Huh-7 cells (243 pmol/g) is indicated by the dotted line.
TABLE 5. Relationship between 2-C-MeGTP concentration in
liver to 2-C-MeG exposure in plasma following a single
oral dose of INX-08189 in rats
INX-08189
dose (mg/kg) N
Liver 2-C-MeGTPa
C24 (ng/g)
Plasma 2-C-MeGb
AUC0-24 (ng  h/ml)
3 6 159 73.4
5 2 412 145.6
10 2 658 322.5
25 2 774 707.9
30 3 1,263 1,024.3
50 3 2,880 2,085.3
150 3 7,130 3,979.2
300 3 10,610 4,309.3
a Mean concentrations for 2-C-MeGTP measured at 24 h.
b Area under the curve values covering 0 to 24 h (AUC0-24) were calculated
from average 2-C-MeG plasma concentrations measured at six time points.
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Pharmacokinetics in cynomolgus monkeys. To determine
the concentration of 2-C-MeGTP in the liver upon INX-08189
oral dosing, four animals were administered 25 mg/kg, and
surgical liver biopsy specimens were collected under anesthesia
at 3 and 8 h postdose. The mean liver 2-C-MeGTP concen-
tration at 3 h was 282 ng/g and increased to 624 ng/g at 8 h
(Table 6). The in vitro EC90 (130.5 ng/g) was exceeded by 2.16-
and 4.78-fold at the respective sample time points.
In an effort to determine the efficiency of INX-08189 extrac-
tion by the liver, cynomolgus monkeys with surgically im-
planted portal vein cannulas were administered 25 mg/kg INX-
08189 by oral gavage. INX-08189 concentrations were
measured in plasma collected from either the portal vein or the
systemic circulation (femoral vein). Following a single oral
dose, INX-08189 was detected in the portal circulation within
30 min of dosing and continued to be measured for up to 4 h
(Fig. 6). At this dose level, INX-08189 was not detected in the
systemic circulation of this animal at any of the time points
tested, whereas the metabolite 2-C-MeG was detected in the
systemic circulation beginning at 1 h postdose. These data
suggest that INX-08189 is efficiently extracted from the portal
circulation by the liver following oral administration, which
results in the formation of the active HCV polymerase inhib-
itor 2-C-MeGTP in liver tissue.
DISCUSSION
The HCV RNA-dependent RNA polymerase encoded by
NS5B is an attractive target for antiviral therapy. The active
site of the enzyme maintains a high degree of sequence con-
servation across all HCV genotypes, allowing the potential for
a pangenotype inhibitor with a high barrier to resistance (22,
23). Some of the most promising and widely studied NS5B
inhibitors are 2-C-methyl nucleoside analogs (5, 6, 34). Within
this family of NS5B inhibitors, the triphosphate form of 2-C-
MeG has been shown to be one of the most potent inhibitors
of NS5B enzyme activity, with an 50% inhibitory concentration
(IC50) of 0.13 M (28). However, the high potency of the
active 2-C-methyl GTP at the biochemical level was not re-
flected in the cell-based replicon assay due to poor cell pene-
tration and a low rate of conversion of the nucleoside to the
active triphosphate (13, 28).
To overcome these limitations, we have utilized an aryloxy-
phosphoramidate approach to modify 2-C-methyl guanosine
analogues. This approach facilitates the direct delivery of the
monophosphorylated nucleoside analogue into the cell, by-
passing the first rate-limiting phosphorylation step (4). The
phosphoramidate prodrug strategy has been used successfully
to improve the HCV antiviral potency of several modified
nucleosides (14, 19, 25, 27). In the case of 2-C-MeG, a striking
improvement in cell-based potency over that of the parent
nucleoside can be achieved (80 fold) with phosphoramidates
incorporating 1-naphthyl as the aryl-leaving group (27). These
prodrugs of 2-C-MeG also have been shown to generate high
concentrations of the active 2-C-MeG triphosphate in liver
tissue following oral administration in mice (24). To further
improve the performance of these compounds, alterations at
the C-2 and C-6 positions of the base were investigated. It was
found that phosphoramidate derivates of 6-O-methyl-2-C-
methyl guanosine demonstrated improvements in cell-based
potency, enhanced lipophilicity, cell permeability, and rapid
intracellular conversion to the active triphosphate in human
hepatocyte cultures (26). As a result of these studies, one
compound that embodied all of these improvements, INX-
08189, was selected for further characterization.
In the current study, the antiviral activity of INX-08189 was
evaluated in the cell-based replicon assay against three HCV
genotypes. The calculated EC50s in genotype 1a, 1b, and 2a
replicons were 12, 10, and 0.9 nM, respectively, making INX-
08189 one of the most potent nucleoside-based NS5B inhibi-
tors characterized to date. This magnitude of potency has been
observed previously only with HCV protease inhibitors and
nonnucleoside polymerase inhibitors (34). The kinetics of
INX-08189 antiviral activity were observed to be rapid, with an
EC50 of 35 nM after only 24 h of exposure with genotype 1b
replicon-containing cells. Coupled with the rapid production of
2-C-methyl GTP observed previously with INX-08189 in hu-
man hepatocytes (26), it is clear that cell entry and the meta-
bolic conversion of INX-08189 is enhanced compared to that
of the parent nucleoside, 2-C-MeG. To determine the con-
centration of intracellular triphosphate required to achieve
viral inhibition, 2-C-MeGTP was quantified in genotype 1b
replicon-expressing Huh-7 cells by LC-MS/MS analysis. After
6 h of incubation, a linear relationship was observed between
INX-08189 concentrations and intracellular 2-C-MeGTP con-
centrations (Table 3). Given these measurements and assum-
ing a hepatocellularity of 1  108 cells in 1 g of liver (37), we
calculated that 84 and 243 pmol of 2-C-MeGTP per g of liver
tissue would provide 50 and 90% levels of viral inhibition,
respectively. These values were used to interpret the pharma-
FIG. 6. Concentrations of INX-08189 and 2-C-methyl guanosine
in plasma after the oral dosing of INX-08189 in cynomolgus monkeys.
Cynomolgus monkeys surgically fitted with portal vein cannulas were
dosed orally with INX-08189 at 25 mg/kg. The analytes measured were
2-C-methyl guanosine concentration in systemic plasma (●), INX-
08189 in portal plasma (), and INX-08189 in systemic plasma (f).
TABLE 6. Intracellular 2-C-MeGTP concentration in liver samples
from cynomolgus monkeys administered a 25-mg/kg oral
dose of INX-08189
Time (h)
2-C-MeGTP liver concn
pmol/g ng/g Avg 
 SD (ng/g)
3 758 407 282 
 177
292 157
8 1,377 740 624 
 165
944 507
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codynamic relevance of the liver concentrations achieved after
the oral administration of INX-08189 in vivo as discussed be-
low. The intracellular half-life of 2-C-MeGTP also was mea-
sured in the replicon cells with a value of approximately 24 h.
This finding is consistent with the half-life of 2-C-MeGTP
observed in primary human hepatocyte cultures (26). The long
intracellular half-life of the active triphosphate suggests that
2-C-MeGTP concentrations in liver sufficient for antiviral ac-
tivity are achievable with once-a-day dosing of INX-08189.
The ability to reduce viral loads rapidly and prevent the
emergence of resistant clones during a lengthy treatment pe-
riod is critical to establishing a robust sustained viral response
in patients. We used the clearance of the genotype 1b replicon
from Huh-7 cells as an in vitro surrogate to measure these
characteristics of INX-08189. In the absence of G418 selection,
concentrations as low as 10 nM INX-08189 (1 EC50) re-
sulted in a 2 log10 decrease in luciferase activity, and at 40
nM INX-08189 (1 EC90) a 7 log10 decrease was observed
during the 14-day culture period. Culture in the presence of
G418 demonstrated that replicon-expressing cells were com-
pletely eliminated after 14 days of treatment with as little as 20
nM INX-08189 (2 EC50). The ability to clear the replicon
and eliminate the rebound of viral replication at such low
concentrations of inhibitor are significant in light of the fact
that other direct-acting antivirals, such as VX-950 (telaprevir)
and HCV-796, were unable to clear the genotype 1b sub-
genomic replicon with up to 15 times their respective EC50s
(23), and PSI-7851, a phosphoramidate nucleotide of 2-F-2-
C-methyl uridine, required 10 times its EC50 to clear the
genotype 1b replicon at day 21 (19).
The S282T substitution in the HCV NS5B gene had been
identified previously as a resistance mutant for 2-C-methyl-
modified nucleosides (20, 28, 30). To determine if INX-08189
selects for this and other mutations in vitro, long-term cultures
of Huh-7 cells containing genotype 1a or 1b replicons were
performed. As expected, the S282T mutation was observed and
confirmed as a resistance mutation leading to an approximately
10-fold change in the EC50. Despite this shift in potency, INX-
08189 still was capable of the complete inhibition of HCV
replication in the S282T mutant replicon, with an EC90 of 344
nM, suggesting only partial resistance to the inhibitory effect of
INX-08189. Since the current standard of care for the treat-
ment of HCV is a combination of IFN- and Rbv, we were
interested in determining what effects the S282T mutation
would have on the potency of these antiviral compounds in
combination. There have been previous reports of enhanced
potency for Rbv against the S282T mutant both at the bio-
chemical and cellular levels (9). Our data confirm these obser-
vations, in that we observed a 6-fold increase in potency for
Rbv against HCV replicons carrying the S282T mutation. It is
well documented that the S282T mutation severely limits the
replication efficiency of HCV (20, 22, 28). A second mutation,
I585T, was observed in the selection studies with INX-08189.
As has been reported previously, the I585T mutation does not
confer drug resistance; however, the presence of this amino
acid change in the genotype 1b replicon improves HCV repli-
cation efficiency (35). We have shown that while compensation
by I585T occurs in both wild-type and S282T-expressing rep-
licons, it does not affect the potency of any of the treatment
drugs tested. Additionally, replicon inhibition studies combin-
ing INX-08189 with Rbv demonstrated a high degree of syn-
ergy against both the wild-type and S282T mutant replicons.
This is unlike some other 2-substituted nucleosides, which are
additive or antagonistic when combined with ribavirin (8).
Whether the synergistic effect is due to the cooperative inhi-
bition of RdRp enzymatic activity by metabolites of INX-08189
and Rbv or is a consequence of the downregulation of com-
peting endogenous nucleotides by Rbv (31) remains to be
determined. These data, coupled with the fact that the S282T
mutation has not been detected in chronically infected HCV
patients at baseline (11) or after treatment with experimental
2-C-methyl-modified nucleoside analogues (21, 33), suggests
that the combination of INX-08189 with Rbv will prove to be
a highly successful strategy to minimize the generation of re-
sistant HCV isolates clinically while at the same time optimiz-
ing viral clearance.
Mitochondrial toxicity has been observed with certain
classes of nucleoside analog drugs that inhibit the activity of
the mitochondrial DNA polymerase , and this effect has been
well studied in the case of reverse transcriptase inhibitors used
to treat HIV infection (1, 15). The potential liability of INX-
08189 with regard to mitochondrial toxicity therefore was as-
sessed in tissue culture studies with both a liver-derived cell
line and a lymphocyte cell line. Incubation in the presence of
INX-08189 for 3 or 14 days indicated no change in the ratio of
mitochondrial genome copy number to cellular DNA. The
results indicate a lack of mitochondrion-specific toxicity for
INX-08189.
The prodrug strategy embodied by INX-08189 complicates
the analysis of pharmacokinetic and pharmacodynamic prop-
erties of the molecule. In rodents, the prodrug is short lived in
the plasma and cannot be measured systemically. In cynomol-
gus monkeys, we have shown that at a dose of 25 mg/kg, the
intact prodrug was present in the portal circulation for a short
time postadministration but was not detected in the systemic
circulation, suggesting that at this concentration of INX-08189
the molecule was efficiently extracted by the liver. Therefore, a
surrogate marker of INX-08189 bioavailability was required to
study its pharmacokinetic and pharmacodynamic properties. In
clinical trials using a similar prodrug strategy to deliver 2-C-
MeGTP to the liver, the nucleoside metabolite 2-C-MeG was
utilized as a surrogate analyte to monitor pharmacokinetics in
HCV patients (17, 18). To validate this approach for INX-
08189, we measured the generation of 2-C-MeGTP, the active
inhibitor of NS5b RdRp, which is present in the liver, and
2-C-MeG in the plasma. In rats where both metabolites could
be measured in the same animals, the data clearly indicate a
linear relationship between the 2-C-MeG AUC24 values and
the concentration of 2-C-MeGTP in the liver at 24 h. The data
for cynomolgus monkeys, although more limited than those of
the rodent studies, were consistent with this finding. The cor-
relative relationship between the two metabolites suggests that
2-C-MeG plasma AUC0-24 values can be used to assess the
delivery of 2-C-MeGTP to the liver in vivo. The rodent data
also showed very good dose proportionality for INX-08189,
demonstrating a linear relationship in the exposure of both
metabolites across a wide range of doses. Based on the mea-
surements of 2-C-MeGTP concentrations required to achieve
90% viral inhibition in vitro, we evaluated if liver 2-C-MeGTP
concentrations achieved in vivo would be sufficient to inhibit
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viral replication. In rats, the concentration of 2-C-MeGTP in
the liver 24 h postdose sufficient for 90% viral inhibition was
achieved after a single oral dose of 3 mg/kg. Since this repre-
sents a trough level of 2-C-MeGTP, multiple dosing would be
expected to further improve triphosphate liver exposures. In
monkeys, concentrations greater than the triphosphate EC90
were measured 6 h after a single dose of 25 mg/kg. 2-C-
MeGTP in rodent liver was found to be long lived, with a
half-life estimated to be greater than 24 h.
Taken together, the in vitro and in vivo data indicate that
INX-08189 is a highly potent inhibitor of HCV with a high
barrier for resistance and good oral pharmacokinetic proper-
ties. The data support the continued advancement of INX-
08189 in clinical development for the treatment of chronic
HCV infections.
ACKNOWLEDGMENTS
Work conducted at the University of Cardiff was supported by a
grant from Inhibitex, Inc., to C.M.
C.M. is a board member and shareholder of Inhibitex, Inc.
We acknowledge Andrea Brancale, Nicola Zonta, and Sarah Jones
for their assistance in modeling studies of the HCV RdRp.
REFERENCES
1. Anderson, P., T. N. Kakuda, and K. A. Lichtenstein. 2004. The cellular
pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase
inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38:743–
753.
2. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of
HCV RNA replication in cell culture. Science 290:1972–1974.
3. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003.
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture.
J. Virol. 77:3181–3190.
4. Cahard, D., C. McGuigan, and J. Balzarini. 2004. Aryloxy phosphoramidate
triesters as pro-tides. Mini-Rev. Med. Chem. 4:371–381.
5. Carroll, S. S., and D. B. Olsen. 2006. Nucleoside analog inhibitors of hep-
atitis C virus replication. Infect. Dis. Drug Targets 6:17–29.
6. Carroll, S. S., et al. 2003. Inhibition of hepatitis C virus RNA replication by
2-modified nucleoside analogs. J. Biol. Chem. 278:11979–11984.
7. Chiu, R. W., et al. 2003. Quantitative analysis of circulating mitochondrial
DNA in plasma. Clin. Chem. 49:719–726.
8. Coelmont, L., et al. 2006. Ribavirin antagonizes the in vitro anti-hepatitis C
virus activity of 2-C-methylcytidine, the active component of valopicitabine.
Antimicrob. Agents Chemother. 50:3444–3446.
9. Cretton-Scott, E., K. Gupta, B. I. Hernandez-Santiago, and M. Larsson.
2010. Compounds and pharmaceutical compositions for the treatment of
viral infections. Patent WO 2010/014134 A1.
10. Delaney, W. E. T., H. Yang, M. D. Miller, C. S. Gibbs, and S. Xiong. 2004.
Combinations of adefovir with nucleoside analogs produce additive antiviral
effects against hepatitis B virus in vitro. Antimicrob. Agents Chemother.
48:3702–3710.
11. Dryer, P. D., et al. 2009. Screening for hepatitis C virus non-nucleotide
resistance mutations in treatment-naive women. J. Antimicrob. Chemother.
64:945–948.
12. Eldrup, A. B., et al. 2004. Structure-activity relationship of purine ribo-
nucleosides for inhibition of hepatitis C virus RNA-dependent RNA poly-
merase. J. Med. Chem. 47:2283–2295.
13. Eldrup, A. B., et al. 2004. Structure-activity relationship of heterobase-
modified 2-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA
replication. J. Med. Chem. 47:5284–5297.
14. Gardelli, C., et al. 2009. Phosphoramidate prodrugs of 2-C-methylcytidine
for therapy of hepatitis C virus infection. J. Med. Chem. 52:5394–5407.
15. Kakuda, T. N. 2000. Pharmacology of nucleoside and nucleotide reverse
transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22:685–
708.
16. Kim, W. R. 2002. The burden of hepatitis C in the United States. Hepatology
36:S30–S34.
17. Lalezari, J., et al. 2009. Antiviral activity, safety and pharmacokinetics of
IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients
with chronic hepatitis C, abstr. LB18. Abstr. 60th Annu. Meet. Am. Assoc.
Study Liver Dis. Liver Meet., Boston, MA.
18. Lalezari, J., et al. 2010. Antiviral activity, pharmacokinetics and safety of
IDX184 in combination with pegylated interferon (pegIFN) and ribavirin
(RBV) in treatment-naive HCV genotype 1-infected subjects. J. Hepatol.
52(Suppl.):S469.
19. Lam, A. M., et al. 2010. PSI-7851, a pronucleotide of beta-D-2-deoxy-2-
fluoro-2-C-methyluridine monophosphate, is a potent and pan-genotype
inhibitor of hepatitis C virus replication. Antimicrob. Agents Chemother.
54:3187–3196.
20. Le Pogam, S., et al. 2006. In vitro selected Con1 subgenomic replicons
resistant to 2-C-methyl-cytidine or to R1479 show lack of cross resistance.
Virology 351:349–359.
21. Le Pogam, S., et al. 2009. No evidence of R7128 drug resistance after up to
4 weeks treatment of GT 1, 2 and 3 hepatitis C virus infected individuals.
J. Hepatol. 50(Suppl.):S348.
22. Ludmerer, S. W., et al. 2005. Replication fitness and NS5B drug sensitivity of
diverse hepatitis C virus isolates characterized by using a transient replica-
tion assay. Antimicrob. Agents Chemother. 49:2059–2069.
23. McCown, M. F., et al. 2008. The hepatitis C Virus Replicon Presents a
Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside
Polymerase or Protease Inhibitors. Anitmicrob. Agents Chemother. 52:
1604–1612.
24. McGuigan, C., et al. 2010. Phosphoramidate ProTides of 2-C-methyl-
guanosine as highly potent inhibitors of hepatitis C virus. Study of their in
vitro and in vivo properties. J. Med. Chem. 53:4949–4957.
25. McGuigan, C., et al. 2009. The application of phosphoramidate ProTide
technology to the potent anti-HCV compound 4-azidocytidine (R1479).
Bioorg. Med. Chem. Lett. 19:4250–4254.
26. McGuigan, C., et al. 2010. Design, synthesis and evaluation of a novel double
pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg.
Med. Chem. Lett. 20:4850–4854.
27. McGuigan, C., P. Perrone, K. Madela, and J. Neyts. 2009. The phosphor-
amidate ProTide approach greatly enhances the activity of beta-2-C-meth-
ylguanosine against hepatitis C virus. Bioorg. Med. Chem. Lett. 19:4316–
4320.
28. Migliaccio, G., et al. 2003. Characterization of resistance to non-obligate
chain-terminating ribonucleoside analogs that inhibit hepatitis C virus rep-
lication in vitro. J. Biol. Chem. 278:49164–49170.
29. Nakabayashi, H., K. Taketa, K. Miyano, T. Yamane, and J. Sato. 1982.
Growth of human hepatoma cell lines with differentiated functions in chem-
ically defined medium. Cancer Res. 42:3858–3863.
30. Olsen, D. B., et al. 2004. A 7-deaza-adenosine analog is a potent and selec-
tive inhibitor of hepatitis C virus replication with excellent pharmacokinetic
properties. Antimicrob. Agents Chemother. 48:3944–3953.
31. Parker, W. B. 2005. Metabolism and antiviral activity of ribavirin. Virus Res.
107:165–171.
32. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to
analyze drug-drug interactions. Antiviral Res. 14:181–205.
33. Rodriguez-Torres, M., et al. 2009. Antiviral activity, pharmacokinetics,
safety, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor
for HCV, following single and 3 day multiple ascending oral doses in healthy
volunteers and patients with chronic HCV infection, abstr. LB17. Abstr. 60th
Annu. Meet. Am. Assoc. Study Liver Dis. Meet., Boston, MA.
34. Schinazi, R. F., L. Bassit, and C. Gavegnano. 2010. HCV drug discovery
aimed at viral eradication. J. Viral Hepat. 17:77–90.
35. Tomei, L., et al. 2003. Mechanism of action and antiviral activity of benz-
imidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent
RNA polymerase. J. Virol. 77:13225–13231.
36. Williams, R. 2006. Global challenges in liver disease. Hepatology 44:521–
526.
37. Wilson, Z. E., et al. 2003. Inter-individual variability in levels of human
microsomal protein and hepatocellularity per gram of liver. Br. J. Clin.
Pharmacol. 56:433–440.
VOL. 55, 2011 INX-08189, A PHOSPHORAMIDATE PRODRUG INHIBITOR OF HCV 1851
 o
n
 April 5, 2012 by Cardiff Univ
http://aac.asm
.org/
D
ow
nloaded from
 
